Environmental Risk Assessment Services
Environmental Risk Assessment (ERA) Services for Human and Animal Drug Products
Environmental Risk Assessment (ERA) Services for Human and Animal Drug Products
At Zenovel, we offer specialized Environmental Risk Assessment services for both human and veterinary drug products. Our comprehensive approach evaluates the potential environmental impacts that may result from the use, storage, and disposal of pharmaceuticals, ensuring compliance with international regulatory frameworks while protecting ecosystems and public health.
For veterinary pharmaceuticals, Zenovel conducts ERAs with a focus on the environmental release of active substances via excretion from treated animals, assessing potential impacts on non-target organisms and ecological systems.
Zenovel offers end-to-end support across all stages of the Environmental Risk Assessment Services process:
The goal of Zenovel’s ERA services is to assess and reduce the risk of adverse environmental impacts—to human health, biodiversity, and ecosystems—while supporting the safe use, storage, and disposal of drug products. We ensure this information is clearly communicated in Summary of Product Characteristics (SmPC) documents and product labeling.
India is a significant player in the global pharmaceuticals sector, characterized by a diverse population and cost-effective infrastructure. However, its potential in clinical research is hindered by complex regulatory challenges that delay innovations and deter investment, affecting the timely market introduction of life-saving drugs. This blog discusses the major obstacles
The FDA issued 466 Form 483s to drug organizations in FY 2022, more than double the previous year, highlighting significant quality failures in the pharmaceutical sector. For startups and scale-ups seeking market approval, the excitement of innovation often conflicts with the strict requirements of current good manufacturing practices (cGMP). Although
Introduction Liposomal Amphotericin-B is a critical antifungal medication that requires careful attention during Bioequivalence (BE) studies. These studies aim to demonstrate the similarity of a generic liposomal Amphotericin B formulation to the reference drug in terms of pharmacokinetics. Zenovel, with its extensive experience in monitoring Amphotericin B studies, can play
In the pharmaceutical and biotechnology industries, obtaining regulatory approval is essential prior to introducing new drugs or biologics to the market. A pivotal aspect of this approval process is the FDA Pre-Approval Inspection (PAI), which involves a comprehensive assessment of manufacturing facilities, processes, and data integrity to ensure adherence to
Risk Based Monitoring (RBM) is a more efficient alternative to traditional clinical trials, focusing on high-risk areas through data-driven insights. It ensures patient safety, data integrity, and regulatory compliance while reducing costs and timelines. However, the success of RBM depends on the competency of monitors, who identify risks, analyze data,
Welcome to the Zenovel Blog! We are a leading provider of drug regulatory consulting and education, focusing on advancing pharmaceutical innovation while ensuring safety and compliance. This blog delves into the essentials of Drug Regulatory Affairs (DRA), covering its scope, career opportunities, and intricate processes involved in bringing new drugs
We provide affordable, innovative, and high-quality solutions to pharma industry with ethics driven research and increasing accessibility to high quality medicine worldwide
Copyright © 2024 Zenovel. All rights reserved.